Rajeev Vibhakar
Concepts (373)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 32 | 2022 | 164 | 10.480 |
Why?
| Cerebellar Neoplasms | 22 | 2022 | 118 | 8.030 |
Why?
| Glioma | 13 | 2022 | 286 | 3.570 |
Why?
| Rhabdoid Tumor | 9 | 2022 | 76 | 3.360 |
Why?
| Brain Neoplasms | 19 | 2021 | 983 | 2.970 |
Why?
| Gene Expression Regulation, Neoplastic | 22 | 2022 | 1200 | 2.900 |
Why?
| Radiation Tolerance | 7 | 2022 | 101 | 2.900 |
Why?
| Cell Cycle Proteins | 8 | 2022 | 573 | 2.630 |
Why?
| Cell Proliferation | 23 | 2022 | 2373 | 1.890 |
Why?
| Teratoma | 5 | 2022 | 91 | 1.880 |
Why?
| Cell Line, Tumor | 27 | 2022 | 2891 | 1.660 |
Why?
| Protein-Tyrosine Kinases | 4 | 2020 | 448 | 1.570 |
Why?
| Proto-Oncogene Proteins c-myc | 4 | 2021 | 131 | 1.400 |
Why?
| Pyrazoles | 7 | 2022 | 400 | 1.380 |
Why?
| Ependymoma | 9 | 2020 | 155 | 1.340 |
Why?
| Nuclear Proteins | 8 | 2017 | 634 | 1.310 |
Why?
| Proto-Oncogene Proteins | 4 | 2022 | 715 | 1.240 |
Why?
| Biomarkers, Tumor | 9 | 2021 | 1060 | 1.220 |
Why?
| Apoptosis | 18 | 2022 | 2616 | 1.190 |
Why?
| Cyclin-Dependent Kinase 6 | 4 | 2020 | 36 | 1.140 |
Why?
| Pyrimidines | 8 | 2019 | 408 | 1.140 |
Why?
| Brain Stem Neoplasms | 4 | 2021 | 79 | 1.130 |
Why?
| Molecular Targeted Therapy | 4 | 2021 | 380 | 1.110 |
Why?
| Radiation-Sensitizing Agents | 2 | 2016 | 37 | 1.070 |
Why?
| Antineoplastic Agents | 10 | 2022 | 2037 | 1.060 |
Why?
| Cell Transformation, Neoplastic | 2 | 2019 | 339 | 1.000 |
Why?
| Genes, myc | 3 | 2020 | 54 | 0.980 |
Why?
| Cellular Senescence | 3 | 2019 | 147 | 0.980 |
Why?
| MicroRNAs | 5 | 2020 | 615 | 0.970 |
Why?
| Pyrimidinones | 4 | 2020 | 94 | 0.970 |
Why?
| Hedgehog Proteins | 6 | 2022 | 172 | 0.900 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 67 | 0.880 |
Why?
| Cell Cycle | 11 | 2017 | 590 | 0.870 |
Why?
| Receptor, trkC | 1 | 2021 | 13 | 0.870 |
Why?
| Receptor, trkB | 1 | 2021 | 30 | 0.850 |
Why?
| Anilides | 3 | 2019 | 78 | 0.840 |
Why?
| Central Nervous System Neoplasms | 4 | 2019 | 125 | 0.820 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 65 | 0.810 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 30 | 0.800 |
Why?
| SMARCB1 Protein | 2 | 2020 | 18 | 0.800 |
Why?
| Neoplastic Stem Cells | 3 | 2019 | 333 | 0.790 |
Why?
| DNA Repair | 1 | 2021 | 184 | 0.760 |
Why?
| Gene Expression Profiling | 14 | 2018 | 1582 | 0.760 |
Why?
| Pteridines | 2 | 2016 | 16 | 0.740 |
Why?
| Deoxycytidine | 1 | 2020 | 146 | 0.740 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 495 | 0.710 |
Why?
| Histones | 4 | 2020 | 539 | 0.690 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 466 | 0.680 |
Why?
| Oligonucleotide Array Sequence Analysis | 10 | 2016 | 778 | 0.680 |
Why?
| Humans | 76 | 2022 | 115146 | 0.660 |
Why?
| Cerebellum | 4 | 2019 | 251 | 0.660 |
Why?
| Vinblastine | 1 | 2016 | 84 | 0.630 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.630 |
Why?
| RNA, Small Interfering | 4 | 2022 | 599 | 0.620 |
Why?
| Bilirubin | 1 | 2016 | 88 | 0.620 |
Why?
| Vincristine | 1 | 2016 | 103 | 0.620 |
Why?
| Radiation, Ionizing | 3 | 2022 | 70 | 0.620 |
Why?
| Blotting, Western | 8 | 2019 | 1294 | 0.600 |
Why?
| Transcription Factors | 4 | 2021 | 1623 | 0.590 |
Why?
| Cell Survival | 8 | 2019 | 1139 | 0.580 |
Why?
| Tumor Cells, Cultured | 7 | 2020 | 1002 | 0.560 |
Why?
| Transcriptome | 5 | 2022 | 685 | 0.560 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 138 | 0.560 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2012 | 61 | 0.560 |
Why?
| Enzyme Inhibitors | 6 | 2020 | 929 | 0.540 |
Why?
| Mutation | 6 | 2021 | 3403 | 0.540 |
Why?
| Child | 27 | 2022 | 17937 | 0.520 |
Why?
| Glioblastoma | 2 | 2020 | 247 | 0.510 |
Why?
| RNA, Messenger | 7 | 2014 | 2835 | 0.490 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2011 | 201 | 0.470 |
Why?
| Child, Preschool | 18 | 2021 | 9680 | 0.430 |
Why?
| Piperazines | 3 | 2022 | 328 | 0.430 |
Why?
| Epigenesis, Genetic | 4 | 2021 | 494 | 0.420 |
Why?
| Azepines | 3 | 2019 | 80 | 0.420 |
Why?
| Prognosis | 9 | 2020 | 3550 | 0.410 |
Why?
| Repressor Proteins | 2 | 2012 | 402 | 0.410 |
Why?
| Mice | 13 | 2022 | 15478 | 0.410 |
Why?
| Intracellular Space | 1 | 2010 | 81 | 0.400 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2020 | 20 | 0.400 |
Why?
| Chromatin | 4 | 2020 | 421 | 0.390 |
Why?
| Genes, Tumor Suppressor | 2 | 2007 | 87 | 0.390 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 1090 | 0.390 |
Why?
| Cisplatin | 3 | 2016 | 276 | 0.380 |
Why?
| Reactive Oxygen Species | 2 | 2022 | 559 | 0.380 |
Why?
| Neoplasm Proteins | 2 | 2012 | 436 | 0.380 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2020 | 779 | 0.370 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1394 | 0.370 |
Why?
| Real-Time Polymerase Chain Reaction | 4 | 2014 | 348 | 0.360 |
Why?
| Drug Screening Assays, Antitumor | 4 | 2021 | 190 | 0.360 |
Why?
| Infratentorial Neoplasms | 2 | 2019 | 36 | 0.360 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2019 | 65 | 0.350 |
Why?
| Quinazolines | 2 | 2022 | 245 | 0.340 |
Why?
| Protein Kinase Inhibitors | 2 | 2014 | 857 | 0.340 |
Why?
| B7 Antigens | 2 | 2020 | 9 | 0.330 |
Why?
| Aurora Kinases | 3 | 2012 | 34 | 0.320 |
Why?
| Single-Cell Analysis | 4 | 2022 | 193 | 0.320 |
Why?
| Animals | 14 | 2022 | 34755 | 0.320 |
Why?
| Mice, Nude | 3 | 2020 | 696 | 0.320 |
Why?
| Aurora Kinase A | 3 | 2012 | 58 | 0.310 |
Why?
| DNA-Binding Proteins | 3 | 2017 | 1426 | 0.310 |
Why?
| Combined Modality Therapy | 6 | 2019 | 1217 | 0.310 |
Why?
| Signal Transduction | 9 | 2021 | 4905 | 0.300 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2020 | 39 | 0.300 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2019 | 197 | 0.300 |
Why?
| Neoplasm Recurrence, Local | 4 | 2022 | 806 | 0.300 |
Why?
| NF-kappa B | 3 | 2019 | 723 | 0.290 |
Why?
| Epigenomics | 3 | 2020 | 90 | 0.290 |
Why?
| Triazoles | 2 | 2019 | 141 | 0.290 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 372 | 0.280 |
Why?
| Bone Morphogenetic Proteins | 2 | 2019 | 133 | 0.280 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2005 | 97 | 0.270 |
Why?
| Autophagy | 2 | 2019 | 317 | 0.260 |
Why?
| Abnormalities, Multiple | 1 | 2005 | 171 | 0.260 |
Why?
| Drug Resistance, Neoplasm | 2 | 2019 | 681 | 0.250 |
Why?
| Survival Rate | 5 | 2020 | 1862 | 0.250 |
Why?
| Female | 23 | 2021 | 63296 | 0.240 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 2 | 2012 | 37 | 0.240 |
Why?
| Genome, Human | 3 | 2014 | 303 | 0.230 |
Why?
| von Willebrand Diseases | 1 | 2022 | 13 | 0.230 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 34 | 0.230 |
Why?
| Spheroids, Cellular | 2 | 2012 | 57 | 0.230 |
Why?
| Disease-Free Survival | 3 | 2016 | 686 | 0.230 |
Why?
| DNA Copy Number Variations | 4 | 2021 | 143 | 0.230 |
Why?
| von Willebrand Factor | 1 | 2022 | 52 | 0.230 |
Why?
| Tumor Microenvironment | 2 | 2022 | 394 | 0.220 |
Why?
| Radiation | 1 | 2021 | 26 | 0.220 |
Why?
| Neural Stem Cells | 2 | 2012 | 102 | 0.220 |
Why?
| Cell Differentiation | 5 | 2020 | 1808 | 0.210 |
Why?
| Pyridines | 3 | 2019 | 499 | 0.210 |
Why?
| RNA, Long Noncoding | 2 | 2021 | 149 | 0.200 |
Why?
| Mice, Transgenic | 3 | 2021 | 2108 | 0.200 |
Why?
| Receptor, EphB4 | 1 | 2020 | 28 | 0.200 |
Why?
| Craniospinal Irradiation | 1 | 2019 | 4 | 0.200 |
Why?
| Colony-Forming Units Assay | 2 | 2012 | 102 | 0.200 |
Why?
| Ephrin-B2 | 1 | 2020 | 44 | 0.200 |
Why?
| Fatal Outcome | 1 | 2021 | 314 | 0.200 |
Why?
| Antigens, Surface | 2 | 1997 | 165 | 0.200 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 63 | 0.200 |
Why?
| Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.190 |
Why?
| Karyopherins | 1 | 2019 | 18 | 0.190 |
Why?
| RNA, Small Nuclear | 1 | 2019 | 31 | 0.190 |
Why?
| Benzamides | 3 | 2019 | 186 | 0.190 |
Why?
| Oncogene Proteins, Fusion | 2 | 2019 | 203 | 0.190 |
Why?
| Infant | 12 | 2021 | 8124 | 0.190 |
Why?
| Kaplan-Meier Estimate | 3 | 2017 | 900 | 0.190 |
Why?
| Adolescent | 12 | 2021 | 18712 | 0.180 |
Why?
| Cell Lineage | 1 | 2021 | 354 | 0.180 |
Why?
| Dose-Response Relationship, Drug | 3 | 2017 | 2187 | 0.180 |
Why?
| Cell Self Renewal | 1 | 2019 | 48 | 0.180 |
Why?
| Proteins | 3 | 2021 | 954 | 0.180 |
Why?
| Male | 20 | 2021 | 60969 | 0.180 |
Why?
| DNA Methylation | 4 | 2021 | 427 | 0.170 |
Why?
| Chemoradiotherapy | 1 | 2019 | 206 | 0.170 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2021 | 894 | 0.170 |
Why?
| Everolimus | 1 | 2017 | 56 | 0.170 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 207 | 0.170 |
Why?
| Base Sequence | 4 | 2012 | 2280 | 0.170 |
Why?
| Recombinational DNA Repair | 1 | 2017 | 6 | 0.170 |
Why?
| Cohort Studies | 6 | 2021 | 5026 | 0.170 |
Why?
| Sulfonamides | 2 | 2022 | 455 | 0.170 |
Why?
| Genes, p16 | 1 | 2017 | 20 | 0.170 |
Why?
| E2F Transcription Factors | 1 | 2017 | 55 | 0.170 |
Why?
| DNA Damage | 2 | 2017 | 371 | 0.160 |
Why?
| Phthalazines | 1 | 2017 | 45 | 0.160 |
Why?
| Morpholines | 1 | 2017 | 113 | 0.160 |
Why?
| Benzodiazepinones | 1 | 2016 | 18 | 0.160 |
Why?
| Chromosome Aberrations | 1 | 2017 | 146 | 0.160 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 23 | 0.160 |
Why?
| Immunophenotyping | 1 | 2017 | 297 | 0.160 |
Why?
| Chloroquine | 1 | 2017 | 65 | 0.160 |
Why?
| Cell Division | 2 | 2010 | 858 | 0.150 |
Why?
| Neoplasm Invasiveness | 2 | 2020 | 452 | 0.150 |
Why?
| Microarray Analysis | 2 | 2017 | 131 | 0.150 |
Why?
| Electric Stimulation Therapy | 1 | 2017 | 68 | 0.150 |
Why?
| Cancer Survivors | 1 | 2019 | 167 | 0.150 |
Why?
| Stem Cells | 1 | 2021 | 548 | 0.150 |
Why?
| Urea | 1 | 2016 | 86 | 0.150 |
Why?
| Up-Regulation | 2 | 2016 | 941 | 0.150 |
Why?
| Lysine | 2 | 2020 | 232 | 0.150 |
Why?
| Phenotype | 2 | 2015 | 2861 | 0.150 |
Why?
| Thiophenes | 1 | 2016 | 104 | 0.150 |
Why?
| Genomics | 3 | 2017 | 518 | 0.150 |
Why?
| Mitosis | 1 | 2016 | 182 | 0.140 |
Why?
| Tumor Suppressor Proteins | 1 | 2017 | 285 | 0.140 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 458 | 0.140 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 194 | 0.140 |
Why?
| Survival Analysis | 2 | 2010 | 1410 | 0.140 |
Why?
| HeLa Cells | 1 | 2016 | 635 | 0.140 |
Why?
| Indoles | 1 | 2017 | 348 | 0.130 |
Why?
| Promoter Regions, Genetic | 3 | 2017 | 1238 | 0.130 |
Why?
| Lymphocyte Activation | 2 | 2002 | 1101 | 0.130 |
Why?
| Precision Medicine | 1 | 2017 | 296 | 0.130 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 735 | 0.120 |
Why?
| Flow Cytometry | 2 | 2019 | 1167 | 0.120 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 199 | 0.120 |
Why?
| Brain | 2 | 2020 | 2723 | 0.120 |
Why?
| Cathepsin B | 1 | 2012 | 16 | 0.120 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 25 | 0.120 |
Why?
| Argonaute Proteins | 1 | 2012 | 26 | 0.120 |
Why?
| Retrospective Studies | 5 | 2019 | 11727 | 0.120 |
Why?
| Cell Movement | 2 | 2020 | 933 | 0.120 |
Why?
| Phosphorylation | 4 | 2020 | 1734 | 0.120 |
Why?
| Genomic Structural Variation | 1 | 2012 | 7 | 0.120 |
Why?
| Wnt Proteins | 1 | 2014 | 148 | 0.120 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 127 | 0.120 |
Why?
| Acetylcysteine | 1 | 2013 | 148 | 0.120 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 224 | 0.120 |
Why?
| Luciferases | 1 | 2012 | 153 | 0.120 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 165 | 0.110 |
Why?
| Tubulin | 1 | 2012 | 124 | 0.110 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2012 | 99 | 0.110 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2017 | 484 | 0.110 |
Why?
| Colorado | 1 | 2022 | 4496 | 0.110 |
Why?
| Telomerase | 1 | 2013 | 223 | 0.110 |
Why?
| Gene Expression Regulation | 1 | 2021 | 2568 | 0.110 |
Why?
| Carrier Proteins | 2 | 2012 | 806 | 0.110 |
Why?
| Acetylation | 1 | 2011 | 222 | 0.110 |
Why?
| Interleukin-6 | 1 | 2015 | 706 | 0.110 |
Why?
| Adenosine | 1 | 2012 | 217 | 0.100 |
Why?
| RNA Interference | 1 | 2012 | 499 | 0.100 |
Why?
| Radiosurgery | 1 | 2014 | 300 | 0.100 |
Why?
| Acetaminophen | 1 | 2013 | 245 | 0.100 |
Why?
| Aging | 1 | 2020 | 1711 | 0.100 |
Why?
| Neoplasm Grading | 2 | 2021 | 247 | 0.100 |
Why?
| Hydroxamic Acids | 2 | 2007 | 88 | 0.100 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2012 | 419 | 0.100 |
Why?
| Superoxides | 1 | 2010 | 238 | 0.100 |
Why?
| Disease Models, Animal | 1 | 2019 | 3826 | 0.100 |
Why?
| Gene Silencing | 2 | 2007 | 176 | 0.090 |
Why?
| Kidney Neoplasms | 1 | 2013 | 330 | 0.090 |
Why?
| T-Lymphocytes | 1 | 1997 | 1807 | 0.090 |
Why?
| Quality of Life | 1 | 2019 | 2250 | 0.090 |
Why?
| Cluster Analysis | 3 | 2017 | 469 | 0.090 |
Why?
| Down-Regulation | 1 | 2010 | 666 | 0.080 |
Why?
| Syndrome | 2 | 2005 | 342 | 0.080 |
Why?
| Neoplasms | 1 | 2021 | 2079 | 0.080 |
Why?
| Scrotum | 1 | 2006 | 24 | 0.080 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2021 | 340 | 0.080 |
Why?
| Nerve Tissue Proteins | 2 | 2012 | 612 | 0.080 |
Why?
| Young Adult | 5 | 2021 | 11032 | 0.080 |
Why?
| Premedication | 1 | 2005 | 43 | 0.070 |
Why?
| Exocrine Pancreatic Insufficiency | 1 | 2005 | 20 | 0.070 |
Why?
| RNA | 1 | 2012 | 779 | 0.070 |
Why?
| Transplantation Chimera | 1 | 2005 | 56 | 0.070 |
Why?
| Neuroblastoma | 1 | 2006 | 130 | 0.070 |
Why?
| Anemia, Aplastic | 1 | 2005 | 31 | 0.070 |
Why?
| Testicular Neoplasms | 1 | 2006 | 84 | 0.070 |
Why?
| Drug Synergism | 2 | 2017 | 359 | 0.070 |
Why?
| Neutropenia | 1 | 2005 | 130 | 0.070 |
Why?
| Computer Simulation | 2 | 2021 | 939 | 0.070 |
Why?
| Case-Control Studies | 1 | 2012 | 3261 | 0.070 |
Why?
| Molecular Sequence Data | 2 | 2008 | 3014 | 0.070 |
Why?
| Transplantation Conditioning | 1 | 2005 | 177 | 0.070 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2197 | 0.060 |
Why?
| Graft vs Host Disease | 1 | 2005 | 223 | 0.060 |
Why?
| Graft Survival | 1 | 2005 | 455 | 0.060 |
Why?
| Weibel-Palade Bodies | 1 | 2022 | 4 | 0.060 |
Why?
| fas Receptor | 1 | 2002 | 99 | 0.060 |
Why?
| Gene Ontology | 1 | 2021 | 43 | 0.060 |
Why?
| Lymphoproliferative Disorders | 1 | 2002 | 87 | 0.060 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 92 | 0.050 |
Why?
| Antigens, CD | 3 | 2002 | 491 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 57 | 0.050 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 140 | 0.050 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 241 | 0.050 |
Why?
| Ifosfamide | 1 | 2020 | 32 | 0.050 |
Why?
| Transcription Factor HES-1 | 1 | 2019 | 7 | 0.050 |
Why?
| Smoothened Receptor | 1 | 2019 | 8 | 0.050 |
Why?
| Risk Factors | 3 | 2021 | 9105 | 0.050 |
Why?
| MyoD Protein | 1 | 2019 | 35 | 0.050 |
Why?
| Gain of Function Mutation | 1 | 2019 | 27 | 0.050 |
Why?
| Astrocytoma | 1 | 2020 | 111 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2019 | 4959 | 0.050 |
Why?
| RNA Splice Sites | 1 | 2019 | 42 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2020 | 233 | 0.050 |
Why?
| Adult | 5 | 2021 | 32202 | 0.050 |
Why?
| Carcinogenesis | 1 | 2021 | 161 | 0.050 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 208 | 0.050 |
Why?
| Apoptosis Regulatory Proteins | 2 | 1997 | 213 | 0.050 |
Why?
| Mice, SCID | 1 | 2019 | 357 | 0.050 |
Why?
| Aminopyridines | 1 | 2019 | 90 | 0.050 |
Why?
| Autoimmune Diseases | 1 | 2002 | 410 | 0.050 |
Why?
| Consensus | 1 | 2021 | 461 | 0.050 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 1997 | 178 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2002 | 606 | 0.040 |
Why?
| RNA Splicing | 1 | 2019 | 252 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 561 | 0.040 |
Why?
| Drug Approval | 1 | 2018 | 79 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 26 | 0.040 |
Why?
| Alternative Splicing | 1 | 2019 | 208 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 19 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 29 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 53 | 0.040 |
Why?
| Treatment Outcome | 3 | 2017 | 9218 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 98 | 0.040 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 87 | 0.040 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1997 | 173 | 0.040 |
Why?
| Ki-67 Antigen | 1 | 2017 | 108 | 0.040 |
Why?
| DNA, Complementary | 1 | 1997 | 288 | 0.040 |
Why?
| Homeodomain Proteins | 1 | 2021 | 499 | 0.040 |
Why?
| Jurkat Cells | 1 | 1997 | 138 | 0.040 |
Why?
| Transfection | 1 | 2019 | 964 | 0.040 |
Why?
| Global Health | 1 | 2019 | 346 | 0.040 |
Why?
| Tyrosine | 1 | 1997 | 241 | 0.040 |
Why?
| Microscopy, Confocal | 1 | 2017 | 316 | 0.040 |
Why?
| Radiotherapy | 1 | 2017 | 197 | 0.040 |
Why?
| Genetic Variation | 1 | 2021 | 825 | 0.040 |
Why?
| Transcriptional Activation | 1 | 2017 | 373 | 0.040 |
Why?
| Cell Culture Techniques | 1 | 2017 | 354 | 0.040 |
Why?
| Canada | 1 | 2016 | 325 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 94 | 0.030 |
Why?
| Zinc Finger Protein Gli2 | 1 | 2014 | 3 | 0.030 |
Why?
| Cytogenetics | 1 | 2014 | 12 | 0.030 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2014 | 20 | 0.030 |
Why?
| Hematopoietic Stem Cells | 1 | 1997 | 374 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2014 | 56 | 0.030 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2014 | 52 | 0.030 |
Why?
| Health Status | 1 | 2019 | 784 | 0.030 |
Why?
| Myeloid Cells | 1 | 2015 | 135 | 0.030 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2014 | 52 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 59 | 0.030 |
Why?
| Middle Aged | 3 | 2021 | 28958 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 550 | 0.030 |
Why?
| Gene Expression | 2 | 2010 | 1538 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 196 | 0.030 |
Why?
| Histone Demethylases | 1 | 2012 | 28 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2016 | 3157 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2017 | 1784 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2013 | 410 | 0.030 |
Why?
| Gene Duplication | 1 | 2012 | 64 | 0.030 |
Why?
| Methylation | 1 | 2012 | 218 | 0.030 |
Why?
| Translocation, Genetic | 1 | 2012 | 118 | 0.030 |
Why?
| Monocytes | 1 | 2015 | 513 | 0.030 |
Why?
| B-Lymphocytes | 1 | 1997 | 817 | 0.030 |
Why?
| Glutathione | 1 | 2013 | 335 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2015 | 545 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 5151 | 0.030 |
Why?
| Genome | 1 | 2012 | 262 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2014 | 1195 | 0.030 |
Why?
| Transforming Growth Factor beta | 1 | 2012 | 463 | 0.020 |
Why?
| Age Factors | 1 | 2017 | 3285 | 0.020 |
Why?
| Disease Progression | 1 | 2016 | 2494 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1997 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1854 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2019 | 4769 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 1964 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2014 | 2940 | 0.020 |
Why?
| Azacitidine | 1 | 2006 | 96 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2012 | 1752 | 0.020 |
Why?
| Risk Assessment | 1 | 2014 | 3215 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2397 | 0.010 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 90 | 0.010 |
Why?
| Lectins, C-Type | 1 | 2002 | 72 | 0.010 |
Why?
| Receptors, Interleukin-2 | 1 | 2002 | 66 | 0.010 |
Why?
| Interleukin-4 | 1 | 2002 | 215 | 0.010 |
Why?
| Cytoplasm | 1 | 2002 | 298 | 0.010 |
Why?
| Interleukin-2 | 1 | 2002 | 403 | 0.010 |
Why?
| Infant, Newborn | 1 | 2011 | 5076 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 2002 | 388 | 0.010 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2002 | 343 | 0.010 |
Why?
| Interferon-gamma | 1 | 2002 | 770 | 0.010 |
Why?
| Restriction Mapping | 1 | 1997 | 93 | 0.010 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 1997 | 33 | 0.010 |
Why?
| Interleukin-7 | 1 | 1997 | 45 | 0.010 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 1997 | 166 | 0.010 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1997 | 81 | 0.010 |
Why?
| Genes | 1 | 1997 | 231 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 1997 | 393 | 0.010 |
Why?
| Bone Marrow | 1 | 1997 | 263 | 0.010 |
Why?
| Calcium | 1 | 2002 | 1208 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1997 | 1316 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1997 | 2161 | 0.010 |
Why?
| Cells, Cultured | 1 | 1997 | 4291 | 0.010 |
Why?
|
|
Vibhakar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|